Valuation: Senzime AB

Market Cap 433M 43.74M 38.88M 36.03M 32.78M 61.86M 4.15B 62.86M 170M 2.17B 164M 161M 6.91B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 433M 43.74M 38.88M 36.03M 32.78M 61.86M 4.15B 62.86M 170M 2.17B 164M 161M 6.91B EV / Sales 2026 *
3.39x
EV / Sales 2027 * 2.12x
Free-Float
40.74%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Senzime AB

1 day+2.80%
1 week-5.65%
Current month-0.18%
1 month-7.86%
3 months-29.90%
6 months-49.91%
Current year-48.98%
1 week 2.64
Extreme 2.635
2.9
1 month 2.35
Extreme 2.35
3.26
Current year 2.35
Extreme 2.35
6
1 year 2.35
Extreme 2.35
6.24
3 years 2.35
Extreme 2.35
9.6
5 years 2.35
Extreme 2.35
24.8
10 years 2.35
Extreme 2.35
28.5
Manager TitleAgeSince
Chief Executive Officer 53 02/05/2023
Director of Finance/CFO 56 31/12/2021
Chief Tech/Sci/R&D Officer 50 31/12/2022
Director TitleAgeSince
Chairman 53 02/05/2023
Director/Board Member 70 31/12/2015
Director/Board Member 63 04/03/2020
Date Insider Type Main position Quantity % Market Cap. Importance
28/09/26 Buy

Director

178,388 0.1135%
25/09/26 Buy

Chief Technology Officer

30,000 0.0191%
24/09/26 Buy

Chief Technology Officer

30,000 0.0191%
Change 5-day change 1-year change 3-year change Capi.($)
+2.80%-5.65%-53.07%-55.64% 43.74M
+0.20%+5.31%-17.82%+13.79% 181B
-0.73%+7.09%-0.31%+32.06% 116B
+0.49%+6.25%-20.20%+11.58% 113B
+3.83%+5.50%-44.18%-6.77% 79.83B
-0.14%+5.27%+6.74%+82.45% 65.06B
+2.79%+2.37%+15.93%+68.64% 54.35B
-1.04%+4.35%+3.50%-26.18% 52.23B
+2.41%+8.18%-12.08%+30.45% 44.15B
-1.90%+2.29%+29.72%+8.98% 32.47B
Average +0.95%+4.19%-9.18%+15.93% 73.86B
Weighted average by Cap. +0.62%+5.59%-9.70%+22.13%

Financials

2026 *2027 *
Net sales 128M 12.89M 11.46M 10.62M 9.67M 18.24M 1.22B 18.53M 50.07M 639M 48.39M 47.36M 2.04B 204M 20.6M 18.31M 16.97M 15.44M 29.14M 1.96B 29.6M 79.98M 1.02B 77.31M 75.66M 3.25B
Net income -68.9M -6.96M -6.18M -5.73M -5.22M -9.84M -660M -10M -27.01M -345M -26.11M -25.55M -1.1B -36.8M -3.72M -3.3M -3.06M -2.79M -5.26M -353M -5.34M -14.43M -184M -13.95M -13.65M -587M
Net Debt - -
Projected Income Statement - Annual - Senzime AB
Logo Senzime AB
Senzime AB (publ.) is a Sweden-based company engaged in the development, manufacture and marketing of biosensors for measuring metabolites in biological fluids, such as human blood and cell culture substrates for the pharmaceutical and healthcare segments. The Company focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.
Employees
59
Date Price Change Volume
16/10/26 SEK 2.755 +2.80% 169,625
15/10/26 SEK 2.680 -3.07% 379,064
14/10/26 SEK 2.765 -0.54% 459,901
13/10/26 SEK 2.780 -0.71% 888,553
12/10/26 SEK 2.800 -4.11% 565,028

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Senzime AB
  1. Stock Market
  2. Stocks
  3. SEZI Stock